Angélique Brzustowski

Characterization and Pharmacological Validation of a Preclinical Model of NASH in Göttingen Minipigs

K. Moreau, V. Paradis, D. Valla, 2021, Journal of clinical and experimental hepatology.

Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19

V. Paradis, D. Thabut, D. Valla, 2022, Biomedicines.

Prospective external validation of a new non‐invasive test for the diagnosis of non‐alcoholic steatohepatitis in patients with type 2 diabetes

V. Paradis, S. Czernichow, D. Valla, 2021, Alimentary pharmacology & therapeutics.

Prospective direct comparison of non‐invasive liver tests in outpatients with type 2 diabetes using intention‐to‐diagnose analysis

V. Paradis, P. Bedossa, S. Pol, 2023, Alimentary pharmacology & therapeutics.

A new NRF2 activator for the treatment of human metabolic dysfunction-associated fatty liver disease

P. Delerive, S. Laouirem, M. Albuquerque, 2023, JHEP reports : innovation in hepatology.